已阅读5页,还剩33页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
甲状腺髓样癌的分子分型及治疗,解放军第一一七医院 戚晓平,概况,Histologic subtypes of thyroid cancer Papillary: approximately 80% of all thyroid malignancies; Follicular and Hrthle: approximately 11%; Medullary: less than 5%-8% ; Anaplastic: less than 2%.,Introduction,Medullary thyroid cancer (MTC) Sporadic MTC: approximately 75%; 50% somatic RET mutations (p.M918T) -predict a poor prognosis Hereditary MTC: approximately 25%; 98% Germline RET mutations, MEN 2A (95%) and MEN 2B (5%) Arises from the neural crest-derived, calcitonin-secreting, parafollicular C cells of the thyroid gland,Introduction,Sporadic MTC: a solitary and unilateral or a palpable cervical lymph node Hereditary MTC: multicentric and bilateral the upper to middle parts of the thyroid lobes,Introduction,Involvement of cervical lymph nodes is an early and common manifestation in the clinical course of the disease, with 35% to 50% or more, another 10% to 15% may have distant metastases at the time of initial presentation; Distant metastatic spread of MTC frequently involves the mediastinal nodes, lung, liver (90%), and bones.,p.C611Y MEN2A,Molecular Aberrations (overexpression ), RET mutations VEGFR-2 MET EGFR FGFR RAS (sMTC-56% KRAS+;12%HRAS) (Mutations in RAS appear to be mutually exclusive of RET abnormalities),Somatic RET mutations,Molecular pathways, PI3K/Akt/mTOR MAPK JNK RAS/ERK Play critical roles in regulating cell proliferation, differentiation, motility, apoptosis, and survival,Diagnosis and Monitoring, FNA,US and CT, MRI or ECT (Ct 500 pg/mL); DNA analysis for the RET germline mutation ATA-2015, ETA-2013, NCCN-2017 Guidelines recommend The MTC specimen is positively stained for Ct, chromogranin A, and CEA or Congo Red.,Diagnosis and Monitoring,Serum-based biomarkers: calcitonin and CEA (50%) Preoperative: CEA(), Ct (-)-poorly differentiated tumors, Rare; Ct 100 pg/mL-predictive MTC; Ct 150 pg/mL, CEA 30 ng/L-regional spread; Ct 3000 pg/mL, CEA 100 ng/L-distant spread.,Predictors of MTC progress, including recurrence and survival,Diagnosis and Monitoring,Serum-based biomarkers: calcitonin and CEA Postoperative: Ct ()- the first sign of tumor recurrence; Ct (-) and sCt (-) -10-year survival rates (SR) of 100%; yearly Ct measurements; Ct doubling times (DT) 1 yr (2yr)- 5- and 10-yr SR of 98% and 95%; CEA DT 1 yr - 5- and 10-yr SR of 100%; Ct DT 1 yr (6mon)- 5- and 10-yr SR of 36% and 18% (25% and 8% ); CEA 1 year - 5- and 10-yr SR of 43% and 21%.,Predictors of MTC progress, including recurrence and survival,Diagnosis and Monitoring,10-yr SR for patients with stages I, II, III, and IV MTC are 100%, 93%, 71%, and 21%, respectively; SR for patients with distant metastases MTC is 51% at 1 yr, 26% at 5 yr, and 10% at 10 yr, respectively.,ATA-2015 Guidelines recommended,MEN2B-de novo RET p.M918T,MEN2B-de novo RET p.M918T,MEN2A-CLA, RET p.C634R/F,Surgical Management of MTC,The minimum extent of surgery is a total thyroidectomy (TT) with bilateral central neck dissection (Bi) (TT+BiLND); TT with ipsilateral lateral compartment neck dissection; (Unilateral lateral LN+, MTC size 1 cm) (TT+Bi+UniLND) TT with bilateral lateral compartment neck dissection. (Bilateral tumors or extensive LN+ on the contralateral side) (TT+Bi+BiLND),Surgical Management of MTC,*Current recommendations for the timing of prophylactic thyroidectomy depends on the risk level of the RET mutation in hereditary MTC (MEN 2).,ATA-2015 Guidelines recommended,Surgical Management of MTC, ATA-D (HST)-MEN 2B 1yr, TT + Bi LND; ATA-AC (MODH)-MEN 2A basal Ct 40 pg/mL, TT without Bi LND is adequate. (Ct 60 ng/L, Elisei R, et al ; Ct 70 ng/L, Qi XP, et al ),Female, 5.5yr; p.C634Y; bilateral MTC; DFS 6yr,Residual and Recurrent Disease,Residual and Recurrent : approximately 50%-80%, postoperation Ct 150 pg/ml, higher probability of distant metastatic disease; US, CT/MRI;,Residual and Recurrent Disease,Cytoreductive (Salvage ) surgery Reduced Ct levels in many patients; Normalization of the Ct levels in up to about 1/3 of patients; The risk of surgical complications,Medical Management of Advanced Metastatic Disease, Cytotoxic chemotherapy in limited patients with rapidly progressive disease minimal benefit Radionuclide therapy I-131 responses only about 30% to 35%, Somatostatin analogs octreotide,Medical Management of Advanced Metastatic Disease,Targeted therapy,Tyrosine kinase receptors and downstream effectors,Medical Management of Advanced Metastatic Disease,Targeted therapy Tyrosine kinase inhibitors(TKIs)- RET, EGFR, VEGFR, and FGFR, MET,Two small-molecule TKIs, vandetanib (Apr 2011) and cabozantinib(Nov 2012), are currently available as approved agents for the treatment of advanced or progressive MTC and provide significant increases in progression-free survival (PFS).,Medical Management of Advanced Metastatic Disease,Vandetanib-RET, EGFR, VEGFR and EGFR two phase 2 (hereditary only) dose daily 300 mg 100 mg PR 20% 16% stable disease 53% 53% median PFS 27.9 months 24 weeks phase 3 in 331 patients (H-S-MTC) 300mg/d; objective response rate (ORR) 45%; median PFS 30.5 months.,QT prolongation (14%),diarrhea (56%), rash (45%), hypertension (32%), headache (26%).,Medical Management of Advanced Metastatic Disease,Cabozantinib-RET, VEGFR and c-MET less suitable for elderly patients for whom the prevalence of cardiovascular risk factors The estimated median PFS with vandetanib is numerically longer than with cabozantinib,Choice: The patients comorbid conditions and the toxicity profile that the patient is willing to bear,Medical Management of Advanced Metastatic Disease,other small-molecule kinase inhibitors sunitinib, sorafenib, and pazopanib
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 42CrMo钢拉杆矫直开裂分析
- 3D打印零件变形分析
- 2022年新课标下数学教学策略探究-以“一次函数”大单元为例
- 2018全国图书情报与档案管理研究生教育与高层次人才培养学术论坛在北京召开
- 2,1,3-苯并噻二唑类溴化物的合成及其性质研究
- 皮肤科抗菌药物治疗的规范化管理
- 企业员工健康培训记录
- 园林植物病虫害防治行业动态
- 高血压药物在肾脏疾病患者中的应用
- 柑橘病虫害防治:守护果实的关键
- 2024年4月自考00522英语国家概况试题
- 期中试题(试题)-2023-2024学年二年级下册数学青岛版
- 海南省 2023-2024 学年高三学业水平诊断(四) 语文试卷及答案
- 2024-2030年中国重庆轨道交通行业市场调查研究及发展战略规划报告
- 字节跳动薪酬制度体系
- 红旗汽车介绍
- 2023-2024学年上海市徐汇区名校中考历史对点突破模拟试卷含解析
- 2024年故宫博物院应届毕业生招聘35人历年高频考题难、易错点模拟试题(共500题)附带答案详解
- 第六章 利润最大化与完全竞争市场
- 三年级下Unit 5 Lets learn.ppt
- 矿山生态修复技术
评论
0/150
提交评论